| Autor: |
Gadowska-Cicha A; Katedry i Kliniki Chorób Wewnetrznych, Angiologii i Medycyny Fizykalnej Slaskiej Akademii Medycznej, Katowicach., Latos W, Niepsuj KJ, Sieroń A |
| Jazyk: |
polština |
| Zdroj: |
Wiadomosci lekarskie (Warsaw, Poland : 1960) [Wiad Lek] 2005; Vol. 58 (5-6), pp. 307-12. |
| Abstrakt: |
The treatment of a form of Lesniowski-Crohn disease (L-CD) which occurs in the upper part of the gastrointestinal tract (GI) in principle is similar to that which is used if other parts of the GI tract are involved in L-CD, however with certain modifications, and these problems are discussed in this paper. The treatment is based on 5-aminosalicylic acid (5-ASA), glucocorticosteroids, antibiotics and immunosuppressive drugs. For patients in whom the conventional therapy doesn't give expected results, the advent of infliximab (biologic agents) has greatly improved treatment possibilities of L-CD. Lesniowski-Crohn disease is not curable either by drugs or by surgery. The goal of treatment in this disease remains the mitigation of symptoms and improvement of the quality of life and at the same time elimination or delaying of the appearance of complications and early and late side effects as a result of treatment. The introduction of biologic agents into the treatment arsenal for inflammatory bowel diseases is a revolutionary step. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
